Harbour BioMed has established a robust pipeline in oncology and immunology since the company was established in early 2017. The current portfolio includes four clinical-stage in-licensed compounds and a rapidly emerging set of therapeutics coming from its internal discovery efforts as well as co-discovery/development collaborations with academic institutions and biopharmaceutical companies.

Harbour BioMed's Global Product Pipeline


Harbour BioMed's Discovery Pipeline

友情链接:澳门网投官网  天空彩票与你同行报码  AS电玩城  利来w66娱乐  奇幻城国际  时时平台娱乐  云顶国际登录  电脑版网投